Copyright: ©Author(s) 2026.
World J Gastroenterol. Nov 28, 2026; 32(44): 122876
Published online Nov 28, 2026. doi: 10.3748/wjg.122876
Published online Nov 28, 2026. doi: 10.3748/wjg.122876
Figure 3 Primary efficacy outcomes.
Comparison of treatment response rate in intent-to-treat populations at week 2. Lansoprazole plus placebo: 51/82 (62.2%, 95%CI: 51.4%-71.9%); flupentixol-melitracen + lansoprazole: 71/82 (86.6%, 95%CI: 77.6%-92.3%). FM: Flupentixol-melitracen; LPZ: Lansoprazole; P + LPZ: Lansoprazole plus placebo.
- Citation: Yin KH, Wang XY, Wang XY, Cheng L, Wang B, Wang QQ, Qiao Y, Tang XR, Yan XJ, Chen SL. Efficacy and safety of neuromodulators combined with proton pump inhibitors for non-erosive reflux disease: A randomized clinical trial. World J Gastroenterol 2026; 32(44): 122876
- URL: https://www.wjgnet.com/1007-9327/full/v32/i44/122876.htm
- DOI: https://dx.doi.org/10.3748/wjg.122876